Pharmicell Total Liabilities

Latest as of September 2025: ₩19.60 Billion KRW ≈ $13.28 Million USD

Pharmicell total liabilities. Based on the latest financial reports, Pharmicell (005690) has total liabilities worth ₩19.60 Billion KRW (≈ $13.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 005690 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Pharmicell (2010–2024)

Total liabilities of Pharmicell from 2010 to 2024. This chart illustrates how Pharmicell's total liabilities have evolved over time, based on quarterly financial data. Explore Pharmicell (005690) investment intensity to see how much of total assets are deployed in long-term investments.

Pharmicell Competitors by Total Liabilities

The table below lists competitors of Pharmicell ranked by their total liabilities.

Company	Country	Total Liabilities
mF International Limited Ordinary Shares NASDAQ:MFI	USA	$21.51 Million
Van de Velde NV BR:VAN	Belgium	€42.28 Million
Checkpoint Therapeutics Inc NASDAQ:CKPT	USA	$17.87 Million
Tsogo Sun JSE:TSG	South Africa	ZAC9.74 Billion
Shen Zhen Australis Electronic Technology Co.Ltd. SHE:300940	China	CN¥360.27 Million
BETTER COLLECTIVE EO-01 F:9C8	Germany	€452.81 Million
Brunel International NV AS:BRNL	Netherlands	€293.65 Million
Funko Inc NASDAQ:FNKO	USA	$466.05 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Pharmicell's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Pharmicell asset portfolio.

Liquidity & Leverage Metrics

Pharmicell Total Liabilities Ratios Explained

Pharmicell total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	10.82	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmicell's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmicell (2010–2024)

The table below shows the annual total liabilities of Pharmicell from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩12.83 Billion ≈ $8.69 Million	+5.80%
2023-12-31	₩12.12 Billion ≈ $8.21 Million	-63.25%
2022-12-31	₩32.98 Billion ≈ $22.35 Million	+8.28%
2021-12-31	₩30.46 Billion ≈ $20.64 Million	+141.01%
2020-12-31	₩12.64 Billion ≈ $8.57 Million	+7.60%
2019-12-31	₩11.75 Billion ≈ $7.96 Million	+1.03%
2018-12-31	₩11.63 Billion ≈ $7.88 Million	+49.86%
2017-12-31	₩7.76 Billion ≈ $5.26 Million	+5.44%
2016-12-31	₩7.36 Billion ≈ $4.99 Million	-56.58%
2013-12-31	₩16.95 Billion ≈ $11.49 Million	-51.36%
2012-12-31	₩34.84 Billion ≈ $23.61 Million	+90.07%
2011-12-31	₩18.33 Billion ≈ $12.42 Million	-7.59%
2010-12-31	₩19.84 Billion ≈ $13.45 Million	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$367.60 Million

₩542.44 Billion KRW

Market Cap Rank

#13580 Global

#397 in Korea

Share Price

₩9040.00

Change (1 day)

+1.57%

52-Week Range

₩8760.00 - ₩20250.00

All Time High

₩25150.00